OXURION: Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO
CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for the ...
Actusnews10h
Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO
Communiqué de la société OXURION du 18/03/2025 - Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO ...
Targeted Oncology13h
Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.